MDT : Analysis & Opinions

  1. MedTech Industry Stock Update - Jan 2014 - Industry Outlook

    January 7, 2014
    MedTech Industry Stock Update - Jan 2014 - Industry Outlook
  2. A Strong Prognosis For Healthcare Stocks

    November 19, 2013
    Despite the healthcare sectors recent torrid run, there’s still plenty to like about stocks in the industry. Aside from tailwinds ...
  3. MedTech Industry Stock Update - Sept 2013 - Industry Outlook

    September 10, 2013
    MedTech Industry Stock Update - Sept 2013 - Industry Outlook
  4. Where Do The Bears Go Next With St. Jude Medical?

    July 18, 2013
    St. Jude continues to defy bearish expectations of major share loss, but the shares aren't exactly cheap today.
  5. Abbott Labs Making Progress On Margins, Now It Needs More Growth

    July 17, 2013
    Abbott's results were just so-so, as both margins and growth need more momentum.
  6. Drugs Driving JNJ, With Slow Progress In Devices And Consumer

    July 17, 2013
    JNJ is getting great performance out of its drug business, but the remainder still lags.
  7. Abbott Adds Two Promising Products

    July 15, 2013
    Abbott makes two solid growth acquisitions that should address large markets.
  8. Stocks Market News for July 11, 2013 - Market News

    July 11, 2013
    Benchmarks finished mixed on Wednesday after the Fed Minutes failed to boost investor sentiment
  9. Medical Device ETFs Slump on Intuitive Surgical Crash - ETF News ...

    July 9, 2013
    Intuitive Surgical's Q2 warning pushed down medical device ETFs on an up day.
  10. CE Mark for St. Jude's CRT-D - Analyst Blog

    June 25, 2013
    St. Jude has won the European CE Mark approval for its MultiPoint Pacing Quadra Assura MP CRT-D, featuring the Quartet lead.
  11. BSX Commences U.S. INTREPID Trial - Analyst Blog

    June 18, 2013
    Boston Scientific initiates clinical trial for its Vercise DBS System in the U.S.
  12. St. Jude Expands Neuro Offerings - Analyst Blog

    June 10, 2013
    St. Jude has entered into an exclusive distribution agreement with Spinal Modulation to sell its Axium Neurostimulator System ...
  13. It Gets A Little Harder From Here For Covidien

    April 29, 2013
    Expectations are the bigger issue for Covidien, as underlying growth is still pretty good on a relative basis.
  14. Broad Weakness Makes It Harder To Like St. Jude Today

    April 18, 2013
    Although I do believe the long-term expectations for St. Jude are increasingly beatable, this could be a frustrating stock ...
  15. Pharma Is Doing All The Pulling For Johnson & Johnson

    April 17, 2013
    Although JNJ reported decent earnings and has some major new drugs lined up - downside risk is definitely still present.
  16. Earnings Preview: Medtronic - Analyst Blog

    February 15, 2013
    Leading medical devices company Medtronic (MDT) is scheduled to report its first quarter fiscal 2013 results before the market ...
  17. CE Mark for BSX's Promus Premier - Analyst Blog

    February 13, 2013
    Boston Scientific (BSX) has expanded its drug eluting stent ("DES") portfolio with the CE Mark approval for the Promus PREMIER ...
  18. Milestone for St. Jude's Heart Implant - Analyst Blog

    February 8, 2013
    Medical devices major St. Jude Medical Inc. (STJ) has reached yet another important clinical landmark by registering the ...
  19. Medtronic Initiates Clinical Study - Analyst Blog

    January 30, 2013
    Leading medical device player Medtronic Inc. (MDT) continues to focus on the promising neuromodulation business. The company ...
  20. Mixed Quarter for Boston Scientific - Analyst Blog

    January 29, 2013
    Boston Scientific (BSX) reported a net income of $60 million or 4 cents per share in the fourth quarter of 2012, a disappointment ...
  21. Microsemi's EPS Lags, Outlook Weak - Analyst Blog

    January 28, 2013
    Microsemi Corporation's (MSCC) adjusted earnings per share (EPS) for the first quarter of fiscal 2013 came in at 41 cents, ...
  22. St. Jude Beats Estimates - Analyst Blog

    January 23, 2013
    St. Jude Medical's (STJ) fourth-quarter adjusted earnings per share of 92 cents topped the Zacks Consensus Estimate by 2 ...
  23. Stryker Follows Its Rivals With A Big Investment In China

    January 22, 2013
    Stryker's acquisition of Trauson is the right deal at the right time.
  24. BSX's ZERO AF's First Success - Analyst Blog

    January 18, 2013
    Boston Scientific Corporation (BSX) recently announced that it has successfully treated the first patient under the ZERO ...
  25. Medtronic Expands AF Product Line - Analyst Blog

    January 17, 2013
    Leading medical devices player, Medtronic (MDT) has strengthened its growing atrial fibrillation (AF) business. This is on ...
  26. St. Jude Gets FDA Warning - Analyst Blog

    January 15, 2013
    Medical devices major, St. Jude Medical Inc. (STJ) has received a warning letter from the U.S. Food and Drug Administration ...
  27. St. Jude Reports Prelim 4Q Results - Analyst Blog

    January 14, 2013
    Medical devices major, St. Jude Medical Inc. (STJ) released preliminary results for the 2012-fourth quarter. The company ...
  28. Medtronic Narrows EPS Outlook - Analyst Blog

    January 8, 2013
    Recently, medical devices major - Medtronic, Inc. (MDT) provided an update on its fiscal 2013 earnings per share (EPS) guidance. ...
  29. St. Jude Commences Ilumien I Trial - Analyst Blog

    December 20, 2012
    Medical devices major, St. Jude Medical Inc. (STJ) has enrolled the first patient for its Ilumien I clinical study. The study ...
  30. BSX Initiates Ingevity Trial - Analyst Blog

    December 19, 2012
    Boston Scientific Corporation (BSX) recently commenced a trial for its next-generation Ingevity pacing leads. The first patient ...
  31. FDA OKs Insulet's Smaller OmniPod - Analyst Blog

    December 17, 2012
    Insulet Corporation (PODD), a leading tubeless insulin pump maker, has won 510(k) Food and Drug Administration (FDA) approval ...
  32. New Product from Medtronic - Analyst Blog

    December 12, 2012
    Medtronic Inc (MDT), the world's leading spinal technology company, announced the launch of the latest addition to its cervical ...
  33. St. Jude to Repurchase $1B Shares - Analyst Blog

    November 30, 2012
    In its concerted effort to increase shareholder's value, medical devices major, St. Jude Medical Inc. (STJ) recently announced ...
  34. Smith & Nephew's Costly Deal

    November 29, 2012
    Smith & Nephew is having to pay a pretty hefty price for this growth injection and this just isn't a sustainable long-term ...
  35. CE Mark Approval for STJ's Assura - Analyst Blog

    November 29, 2012
    Medical devices major, St. Jude Medical (STJ) recently won the European CE Mark approval for its line of implantable cardioverter ...
  36. Will Bad Leads Lead St. Jude Astray?

    November 26, 2012
    St. Jude needs to fix its problems with high-voltage leads in order to restore investor confidence.
  37. Alnylam-Tekmira Settle Up - Analyst Blog

    November 19, 2012
    Alnylam Pharmaceuticals, Inc. (ALNY) and Tekmira Pharmaceuticals Corporation recently signed a new licensing agreement and ...
  38. Still Neutral on DexCom - Analyst Blog

    November 15, 2012
    Following the third quarter earnings release, we are maintaining our long-term 'Neutral' recommendation on DexCom (DXCM), ...
  39. Boston Scientific to Buy Vessix - Analyst Blog

    November 12, 2012
    Viewing the huge potential of the renal denervation market, Boston Scientific (BSX) plans to acquire Vessix Vascular, which ...
  40. DexCom Continues to Incur Loss - Analyst Blog

    November 5, 2012
    DexCom (DXCM), a player in the glucose monitoring market, reported third quarter 2012 loss per share of 25 cents, higher ...
  41. Greatbatch Beats Ests, Profits Dip - Analyst Blog

    October 26, 2012
    Greatbatch, Inc.'s (GB) third-quarter 2012 adjusted earnings per share of 46 cents beat the Zacks Consensus Estimate of 44 ...
  42. Another Dismal Quarter for BSX - Analyst Blog

    October 18, 2012
    Boston Scientific (BSX) reported a net loss of $725 million or 52 cents per share in the third quarter of 2012, a disappointment ...
  43. BSX Progresses on TAVR Trial - Analyst Blog

    October 11, 2012
    Boston Scientific Corporation (BSX) is making good progress in the REPRISE II clinical trial. The company enrolled its first ...
  44. BSX to Expand Electrophysiology Biz - Analyst Blog

    October 10, 2012
    Boston Scientific Corporation (BSX) plans to acquire Rhythmia Medical, which would strengthen its foothold in the electrophysiology ...
  45. New Spine Device from Medtronic - Analyst Blog

    October 9, 2012
    To overcome the ongoing difficulties and challenges in the spinal business, leading medical device player Medtronic, Inc. ...
  46. St. Jude Reports Positive Data - Analyst Blog

    October 5, 2012
    Medical devices major, St. Jude Medical, Inc. (STJ) recently announced results from a large-scale clinical study of peripheral ...
  47. MDT Progresses on Renal Denervation - Analyst Blog

    October 4, 2012
    Leading medical devices player, Medtronic (MDT) has progressed with respect to its renal denervation program. The company ...
  48. MedTech Industry Stock Outlook - Oct. 2012 - Zacks Analyst Interviews

    October 2, 2012
    The global medical devices industry is fairly large, intensely competitive and highly innovative. A regulated industry, MedTech ...
  49. MedTech Industry Stock Outlook - Oct. 2012 - Industry Outlook

    October 2, 2012
    The global medical devices industry is fairly large, intensely competitive and highly innovative. A regulated industry, MedTech ...
  50. Medtronic Expands in China - Analyst Blog

    October 1, 2012
    Recently, the medical device players have shifted focus towards emerging markets, especially China. Medtronic (MDT), in line ...
  51. STJ's Eon Family Wins CE Mark - Analyst Blog

    September 24, 2012
    Medical devices major, St. Jude Medical, Inc. (STJ) recently won European CE Mark approval for its Eon family of neurostimulators ...
  52. BSX to Acquire BridgePoint Medical - Analyst Blog

    September 24, 2012
    Boston Scientific (BSX), in order to strengthen its interventional cardiology portfolio, has signed a definitive agreement ...
  53. Medtronic Remains Neutral - Analyst Blog

    September 14, 2012
    We have reaffirmed our Neutral recommendation on Medtronic (MDT) with a target price of $44.00. During the first quarter ...
  54. Greatbatch Remains Neutral - Analyst Blog

    September 4, 2012
    We reiterate our Neutral recommendation on Greatbatch, Inc. (GB) following its second quarter results. In the reported quarter, ...
  55. MDT Progresses in CoreValve Trial - Analyst Blog

    September 4, 2012
    Leading medical devices player, Medtronic (MDT) has progressed with respect to its CoreValve US pivotal trial. The company ...
  56. Medtronic Presents Positive Data - Analyst Blog

    August 28, 2012
    Leading medical devices player, Medtronic (MDT), recently presented positive data from the Symplicity HTN-2 clinical trial ...
  57. Expanded Use for BSX' Watchman - Analyst Blog

    August 27, 2012
    With the CE Mark approval based on the results from the ASAP (ASA Plavix) study,  Boston Scientific's (BSX) Watchman Left ...
  58. Expanded Use for BSX's Watchman - Analyst Blog

    August 27, 2012
    With the CE Mark approval based on the results from the ASAP (ASA Plavix) study,  Boston Scientific's (BSX) Watchman Left ...
  59. Medtronic Expands Portfolio - Analyst Blog

    August 27, 2012
    Leading medical devices player, Medtronic (MDT) has strengthened its growing atrial fibrillation ("AF") business as it has ...
  60. The Week Ahead In Healthcare (August 20)

    August 21, 2012
    Although this has been a solid year for med-tech, some sub-sectors are starting to lag a bit during this late summer rally.
  61. Alnylam Earns Milestone Payment - Analyst Blog

    August 6, 2012
    Alnylam Pharmaceuticals Inc. (ALNY) recently earned development milestone payment of $3.2 million from GlaxoSmithKline (GSK). ...
  62. Greatbatch's 2Q Mixed, Profit Drops - Analyst Blog

    July 26, 2012
    Greatbatch, Inc. (GB) reported second-quarter 2012 adjusted (excluding one-time items) earnings per share of 43 cents, in ...
  63. Edwards' Mixed 2Q, Revises View - Analyst Blog

    July 25, 2012
    Edwards Lifesciences Corporation (EW) reported net income of $67.8 million or 57 cents per share in the second quarter of ...
  64. Earnings Preview: EW - Analyst Blog

    July 23, 2012
    Edwards Lifesciences Corporation (EW) is scheduled to release its second quarter fiscal 2012 results on Tuesday, July 24, ...
  65. MDT Progresses with CoreValve Trial - Analyst Blog

    July 20, 2012
    Leading medical devices player, Medtronic (MDT), has enrolled the first patient in the Surgical Replacement and Transcatheter ...
  66. Greatbatch to Build R&D Centre - Analyst Blog

    July 20, 2012
    Medical technologies company, Greatbatch Inc. (GB) recently announced that it will set up an Active Implantable Medical Device ...
  67. Greatbatch to Relocate Ortho Unit - Analyst Blog

    July 5, 2012
    Medical technology company, Greatbatch Inc. (GB) recently proposed to relocate Greatbatch Medical's orthopedics manufacturing ...
  68. BSX Progresses on Prevail Trial - Analyst Blog

    July 3, 2012
    With its core segments of stents and defibrillators struggling, leading medical devices player Boston Scientific Corporation ...
  69. Zimmer Expands US Spinal Portfolio - Analyst Blog

    June 27, 2012
    Zimmer Holdings (ZMH) has strengthened its spinal portfolio in the US with the introduction of TM Ardis interbody system. ...
  70. Obamacare's Future in the Balance - Analyst Blog

    June 27, 2012
    The country is awaiting a major event later this week with the Supreme Court scheduled to deliver a decision on the Patient ...
  71. Cyberonics Reaffirmed at Neutral - Analyst Blog

    June 25, 2012
    We have reiterated our Neutral recommendation on Cyberonics Inc. (CYBX) with a target price of $46.00, following our assessment ...
  72. MDT Stent Chosen for FDA Pilot Study - Analyst Blog

    June 25, 2012
    Last week, leading medical devices player, Medtronic (MDT) announced that the US Food and Drug Administration ("FDA") has ...
  73. Balanced View on Medtronic - Analyst Blog

    June 21, 2012
    We reiterate our Neutral recommendation on Medtronic (MDT) with a target price of $40.00. The company's revenues and earnings ...
  74. St. Jude's AVP4 Gets FDA Approval - Analyst Blog

    June 19, 2012
    Leading medical devices company, St. Jude Medical Inc. (STJ), has received the Food and Drug Administration's ("FDA") approval ...
  75. BSX Sees Prospects in Endoscopy - Analyst Blog

    June 13, 2012
    Earlier this week Boston Scientific Corporation (BSX) reviewed future prospects of its endoscopy business. This business ...
  76. New Licensing Deal for Cyberonics - Analyst Blog

    June 12, 2012
    Leading neuromodulation company, Cyberonics Inc. (CYBX) recently entered into an exclusive technology licensing agreement ...
  77. Edwards' GLX Gain IDE Approval - Analyst Blog

    June 12, 2012
    Edwards Lifesciences Corporation (EW) has received conditional Investigational Device Exemption ("IDE") approval from the ...
  78. BSX Wraps Up Cameron Health Deal - Analyst Blog

    June 11, 2012
    With the completion of the Cameron Health acquisition, Boston Scientific's (BSX) portfolio now includes subcutaneous implantable ...
  79. Medtronic's Endurant II Now in US - Analyst Blog

    June 8, 2012
    Leading medical devices player, Medtronic (MDT) has strengthened its Endovascular portfolio with the US launch of Endurant ...
  80. Boston Scientific Busy with Stents - Analyst Blog

    June 6, 2012
    BostonScientific (BSX) has expanded its drug eluting stent ("DES") portfolio with approval from the US Food and Drug Administration ...
  81. Boston Scientific Innova Has CE Mark - Analyst Blog

    May 15, 2012
    Boston Scientific Corporation (BSX) has strengthened its stent portfolio in Europe with the CE Mark approval and subsequent ...
  82. Stryker Appears Quite Sound

    April 23, 2012
    Stryker's stock should eventually follow the underlying fundamentals of its sound businesses.
  83. Fundamentals Point to 7 Dividend Payers

    February 24, 2012
    Accelerating dividend payments are among the fundamental metrics fund manager Robert Zagunis tracks in his stock-selection ...
  84. Value At Abbott Labs Balances A Lot Of Growth Optimism

    February 14, 2012
    Growth expectations may be too high for Abbott.
  85. The 10 Must-Know Market Forces for 2012

    February 14, 2012
    For the first time since 2007, investors have multiple ways to succeed this year. Understanding how the lingering effects ...
  86. Abbott Labs Dividing Its Growth And Income Potential

    January 26, 2012
    With the coming split of operations, Abbott Labs investors will better be able to choose between growth and income.
  87. OM Group - Just Another Cheap Commodity Play, Or Something More?

    January 17, 2012
    OM Group is seeing multiple cyclical downturns, but looks cheap.
  88. Don't Count Out Healthcare Stocks

    January 6, 2012
    The healthcare sector remains bogged down in a mire of regulation and dwindling spending.
  89. 2011 - Another Sick Year For Larger Med-Tech

    December 29, 2011
    Larger healthcare companies are still getting sickly returns in the market.
  90. Uncertainty Still Means Discount For WellPoint

    November 30, 2011
    Uncertainty still means discount for WellPoint.
  91. St. Jude Still A Patient Trade

    October 24, 2011
    St. Jude's growth is lacking, today. However, it could be a winner for the patient investor.
  92. Protect On The Downside With J&J

    October 21, 2011
    J&J trades at a reasonable forward P/E and offers investors downside protection.
  93. The Perpetual Boston Scientific Turnaround Story

    August 4, 2011
    Another quarter brings another hope for better days at BSX.
  94. St. Jude's Healthy Prognosis

    July 26, 2011
    St Jude continued to grow robustly during its second quarter.
  95. Baxter Looking Pale In Comparison To Rivals

    July 26, 2011
    A handful of health care peers trade at more appealing earnings multiples than Baxter.
  96. Better Budgets, Better Times For Robots

    July 12, 2011
    With healthier budgets at hospitals, robots are looking better and better.
  97. Dividend Payers In Medical Technology

    June 21, 2011
    The healthcare sector has grown faster than the economy and seems poised to continue to do so...
  98. Johnson & Johnson Surrenders In Stents

    June 17, 2011
    JNJ makes a tough and surprising, but ultimately wise, decision.
  99. Will A Shake Up Cure AngioDynamics' Malaise?

    June 14, 2011
    AngioDynamics is shaking things up in the hopes of rekindling growth.
  100. Fattening Up A Portfolio While Slimming Down

    June 1, 2011
    With the numbers of overweight and obese people growing globally, investors may want to consider stocks on the front lines ...
  101. Mergers In Orthopedics Could Heat Up Stocks

    May 18, 2011
    Major med-tech players have picked up where they left off before the recession and credit crisis.
  102. JNJ And Synthes: A Good Deal With Some Questions

    April 28, 2011
    The JNJ-Synthes deal is not a surprise, but the terms of the deal are curious.
  103. J&J Beats Analyst Expections, But Not Its Rivals

    April 25, 2011
    Tangible signs of sustained sales growth and consistent profit expansion are still absent at J&J.
  104. Despite The Noise, Abbott Still A Value

    April 25, 2011
    Abbott has made some curious moves of late, but the value is still there.
  105. Can St. Jude Live Up To Newfound Expectations?

    April 25, 2011
    St. Jude faces something it has rarely seen in the past - high expectations.
  106. DexCom Shows Diabetes Still A Growth Industry

    March 9, 2011
    DexCom shows that, although times are tough, people will still adopt better technology.
  107. Multiple Value Creation Opportunities For Stryker

    February 2, 2011
    Stryker could end up being acquired by a larger rival, but company growth trends remain appealingly robust in their own right.
  108. Risk With Little Reward At Johnson & Johnson

    January 27, 2011
    A number of Johnson & Johnson rivals trade at equally appealing valuations and have their acts together in terms of product ...
  109. Med-Tech Choice Is Simply Intuitive

    January 25, 2011
    Intuitive posted reassuring growth, but needs to continue penetrating new markets.
  110. 2010: The Year In Med-Tech Deals

    December 29, 2010
    2010 was a relatively slow year for deals in the med-tech sector.
  111. Nordson's Growth Story Sticks

    December 20, 2010
    With broad economic exposure and over 20% order growth, Nordson results point to the ongoing recovery.
  112. Stryker Moves On From A Long Mistake

    December 8, 2010
    Stryker finally rids itself of a long-failed product. Find out if this othopedic devices manufacturer is poised for growth.
  113. Merck Makes A Smart Buy

    December 3, 2010
    Merck is making an exciting bet on a possible diabetes breakthrough.
  114. FDA Locked And Loaded For MELA Sciences

    November 16, 2010
    A harsh FDA review sends MELA down sharply before a pivotal panel meeting.
  115. Allergan Winning Wall Street's Beauty Pageant

    November 3, 2010
    Allergan's earnings aren't special, but the stock is basking in Wall Street's love. Is it simply a case of lipstick on a ...
  116. NuVasive Stumbles, Investors Get A Concussion

    November 2, 2010
    A once-dependable growth stock disappoints, and pays for it.
  117. J&J Will Get Well Soon

    October 25, 2010
    At the current time, finding investment appeal in Johnson & Johnson's stock is difficult.
  118. Boston Scientific Has A Long Road Back

    October 21, 2010
    Boston Scientific is priced to do almost nothing, but that may underestimate the potential of operating improvement.
  119. St. Jude Is Fine Today But What About Tomorrow?

    October 21, 2010
    St. Jude is holding its own, but investors will demand more if the stock is to outperform.
  120. St. Jude Sews Up A Lucrative Niche

    October 19, 2010
    St. Jude pays big price tag, but gets a potential blockbuster in return.
  121. Money To Be Made In Medical Devices

    September 22, 2010
    New advances in medical devices will not only help patients live better lives, but they'll power portfolios as well.
  122. It's Not All About The Housing Market

    September 17, 2010
    It may seem hopeless investing in stocks today, but some businesses thrive despite a bad housing market and high unemployment.
  123. Stryker In Oversold Territory

    August 26, 2010
    A pessimistic stock market and weak Medtronic results have sent shares of Stryker back toward their lows over the last year.
  124. Investing For The Diabetes Epidemic

    July 30, 2010
    Sadly, diabetes is quickly becoming a global epidemic. Nearly 300 million people suffer from the disease worldwide.
  125. Johnson & Johnson Needs A Catalyst

    July 22, 2010
    It's difficult to find a catalyst for growth to return to more historical levels at Johnson & Johnson.
  126. Four Companies Shifting Into Overdrive

    June 11, 2010
    Market volatility over the past few years has presented M&A opportunities for best-in-breed companies.
  127. Intuitive Surgical - Are Robots To Be Trusted?

    June 1, 2010
    Can Intuitive Surgical produce the growth necessary to validate the stock's lofty perch?
  128. Covidien Shuffles The Deck

    June 1, 2010
    Covidien made a surprising deal to get into peripheral vascular therapies - a business with big growth potential.
  129. Great Dividend Payers In Medical Technology

    May 21, 2010
    Dividend-paying stocks are not common in medical technology, but these four proven winners deliver the goods.
  130. Becton Dickinson More Interesting Than You Think

    May 3, 2010
    Becton Dickinson is often dismissed as "boring" but a diversified cash-generating business with real growth shouldn't be.
  131. Can Boston Scientific Ever Get It Right?

    April 30, 2010
    Boston Scientific has been a perrenial underperformer. Can the company turn it around?
  132. Boston Scientific Looking Sickly

    April 29, 2010
    Boston Scientific's history will go a long way in paving the path for a recovery, but until investors see those signs, this ...
  133. Small Med-Tech Names You Should Know

    April 15, 2010
    These three med-tech names aren't well-known by most investors, but they should be.
  134. 4 More Stocks The Insiders Love

    February 12, 2010
    These insider buys are worth a second look.
  135. J&J Looks To Get Back On Track

    July 15, 2009
    Investors are waiting for J&J to return to its heyday of double-digit growth.
  136. Diversification Alone Is Not Enough

    April 9, 2009
    Opinions on the number of stocks for a diversified portfolio vary, but locking in low expenses leaves little room for disagreement.
  137. An Even Rarer Stryker Buying Opportunity

    February 23, 2009
    Four months ago there was a buying opportunity for Stryker but is the opportunity better or worse now?
  138. Microsemi Not Your Average Semi Stock

    November 17, 2008
    Microsemi isn't a typical semiconductor stock - and that's a good thing these days.
  139. A Rare Stryker Buying Opportunity

    October 21, 2008
    A proven performer is taking a beating in the market. Even with slower growth, Stryker's a likely winner.
  140. Will St. Jude Keep The Beat?

    October 20, 2008
    St. Jude is going to face tougher competition in the core CRM business, but that shouldn't alter the basic "growth at a reasonable ...
  141. Abbott Labs A Salve For The Wounded Portfolio

    October 16, 2008
    Abbott Labs announced a new buyback program and development of a revolutionary heart stent. Long-term investors should take ...
  142. Boston Scientific Finally Showing Signs Of Health

    April 29, 2008
    The medical device maker has been ailing recently, but its vital signs suggest it will bounce back.
  143. December Q&A Encore

    December 10, 2007
    Questions include: Which companies could be headed to bankruptcy, and why should you avoid airline stocks?
  144. Medical Devices: Selloff Safe Haven (IHI)

    August 24, 2007
    Medical equipment makers made it through the recent selloff relatively unscathed. One ETF allows investors to play the whole ...
  145. Steady Heart Required (EVVV, SPNC, POSS)

    August 20, 2007
    We examine a trio of small-cap firms who focus on cardiovascular problems. Is it worth investing in potential?
  146. As Good As New (BDX, BSX, ZMH)

    May 11, 2007
    A look at several companies poised to meet the healthcare needs of the aging baby-boomer generation
  147. Boston Scientific Shaken, But Not Stirred (BSX)

    November 8, 2006
    Boston Scientific looks poised for higher per share valuations in the future.
Investing News
  1. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
  2. What $200,000 Will Buy In The Atlanta Real Estate Market

    Atlanta housing prices are up from last year, but they're still lower than the national median. ...
  3. Bubble Bursting? Only For Biotech & Internet Stocks

    The recent sluggish performance of U.S. stocks is leading some market watchers to question ...
  4. What $300,000 Will Buy In The Riverside/San Bernardino Real Estate Market

    The median list price for the San Bernardino/Riverside, Calif. market is $292,800, up 24.6% ...
  5. What Is Worse Than Being At Risk?

    You may have heard the old adage: “What is worse than being lost? Not knowing you are lost.” ...
  6. Can Paying Off Your Mortgage Early Hurt Your Net Worth?

    Saving your money and making double or even triple payments on a mortgage may sound productive, ...
Trading Center